Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 181

1.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group.

N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.

PMID:
30207920
2.

Involvement of Mitochondria in Neurodegeneration in Multiple Sclerosis.

Kozin MS, Kulakova OG, Favorova OO.

Biochemistry (Mosc). 2018 Jul;83(7):813-830. doi: 10.1134/S0006297918070052. Review.

PMID:
30200866
3.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators.

N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583.

PMID:
30157388
4.

Research Uncovers How Commensal Bacteria Contribute to Multiple Sclerosis.

Hampton T.

JAMA. 2018 Aug 7;320(5):429-430. doi: 10.1001/jama.2017.12863. No abstract available.

PMID:
30087987
5.

Clinical adverse effects of natalizumab: Protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails.

Li H, Shi FH, Huang SY, Zhang SG, Gu ZC, Wei JF.

Medicine (Baltimore). 2018 Jul;97(28):e11507. doi: 10.1097/MD.0000000000011507. Review.

6.

There is no benefit in the use of postnatal intravenous immunoglobulin for the prevention of relapses of multiple sclerosis: findings from a systematic review and meta-analysis.

Rosa GR, O'Brien AT, Nogueira EAG, Carvalho VM, Paz SC, Fragoso YD.

Arq Neuropsiquiatr. 2018 Jun;76(6):361-366. doi: 10.1590/0004-282X20180041. Review.

7.

Are adverse outcome rates higher in multiple sclerosis patients after total hip arthroplasty?

Newman JM, Khlopas A, Sodhi N, Curtis GL, Sultan AA, George J, Higuera CA, Mont MA.

Bone Joint J. 2018 Jul;100-B(7):875-881. doi: 10.1302/0301-620X.100B7.BJJ-2017-1569.R1.

PMID:
29954205
8.

Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial.

Simone M, Viterbo RG, Margari L, Iaffaldano P.

BMC Neurol. 2018 Jun 8;18(1):82. doi: 10.1186/s12883-018-1087-3.

9.

A Cognitive Occupation-Based Programme for People with Multiple Sclerosis: A Study to Test Feasibility and Clinical Outcomes.

Reilly S, Hynes SM.

Occup Ther Int. 2018 May 2;2018:1614901. doi: 10.1155/2018/1614901. eCollection 2018.

10.

Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis.

Buonomo AR, Zappulo E, Viceconte G, Scotto R, Borgia G, Gentile I.

Expert Opin Drug Saf. 2018 Jul;17(7):709-717. doi: 10.1080/14740338.2018.1483330. Epub 2018 Jun 11. Review.

PMID:
29848085
11.

Gut Microbiota in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Current Applications and Future Perspectives.

Chu F, Shi M, Lang Y, Shen D, Jin T, Zhu J, Cui L.

Mediators Inflamm. 2018 Apr 2;2018:8168717. doi: 10.1155/2018/8168717. eCollection 2018. Review.

12.

Determinants of Cognitive Impairment in Patients with Multiple Sclerosis with and without Atrophy.

Eijlers AJC, Meijer KA, van Geest Q, Geurts JJG, Schoonheim MM.

Radiology. 2018 Aug;288(2):544-551. doi: 10.1148/radiol.2018172808. Epub 2018 May 22.

PMID:
29786489
13.

Why Is Cognitive Impairment Present in Multiple Sclerosis? Insights from Functional MRI.

Zivadinov R.

Radiology. 2018 Aug;288(2):552-553. doi: 10.1148/radiol.2018180719. Epub 2018 May 22. No abstract available.

PMID:
29786484
14.

Dysregulated Network of miRNAs Involved in the Pathogenesis of Multiple Sclerosis.

Dolati S, Marofi F, Babaloo Z, Aghebati-Maleki L, Roshangar L, Ahmadi M, Rikhtegar R, Yousefi M.

Biomed Pharmacother. 2018 Aug;104:280-290. doi: 10.1016/j.biopha.2018.05.050. Epub 2018 May 25. Review.

PMID:
29775896
15.

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.

Fernández O, Izquierdo G, Fernández V, Leyva L, Reyes V, Guerrero M, León A, Arnaiz C, Navarro G, Páramo MD, Cuesta A, Soria B, Hmadcha A, Pozo D, Fernandez-Montesinos R, Leal M, Ochotorena I, Gálvez P, Geniz MA, Barón FJ, Mata R, Medina C, Caparrós-Escudero C, Cardesa A, Cuende N; Research Group Study EudraCT 2008-004015-35.

PLoS One. 2018 May 16;13(5):e0195891. doi: 10.1371/journal.pone.0195891. eCollection 2018.

16.
17.

Effect of photobiomodulation treatment in the sublingual, radial artery region, and along the spinal column in individuals with multiple sclerosis: Protocol for a randomized, controlled, double-blind, clinical trial.

da Silva T, da Silva FC, Gomes AO, Viana AO, Gonçalves MLL, Rodrigues MFSD, Horliana ACRT, da Silva DFT, Chavantes MC, Fragoso YD, Branco LP, Motta LJ, Fernandes KPS, Mesquita-Ferrari RA, Bussadori SK.

Medicine (Baltimore). 2018 May;97(19):e0627. doi: 10.1097/MD.0000000000010627.

18.

Lower Aerobic Endurance Linked to History of Depression in Multiple Sclerosis: Preliminary Observations.

Chapman KR, Anderson JR, Calvo D, Pollock BS, Petersen J, Gerhart H, Ridgel A, Spitznagel MB.

J Neurosci Nurs. 2018 Jun;50(3):167-170. doi: 10.1097/JNN.0000000000000360.

PMID:
29727394
19.

Sexual Function in Young Individuals With Multiple Sclerosis: Does Disability Matter?

Calabrò RS, Russo M, Dattola V, De Luca R, Leo A, Grisolaghi J, Bramanti P, Quattrini F.

J Neurosci Nurs. 2018 Jun;50(3):161-166. doi: 10.1097/JNN.0000000000000367.

PMID:
29727393
20.

Neuropsychology in the Integrated MS Care Setting.

Foley FW, Portnoy JG.

Arch Clin Neuropsychol. 2018 May 1;33(3):330-338. doi: 10.1093/arclin/acy003. Review.

PMID:
29718075

Supplemental Content

Loading ...
Support Center